EurekaMag
+ Translate
+ Most Popular
Gaucher's disease;thirty-two years experience at Siriraj Hospital
A study of Macrobathra Meyrick from China (Lepidoptera, Cosmopterigidae)
First occurrence in ores of tetragonal chalcocite
Effects of trace element nutrition on sleep patterns in adult women
N.Z. range management guidelines. 2. Design of grazing management systems for tussock country
A case of lipoma of the esophagus
A revision of world Acanthosomatidae (Heteroptera: Pentatomidae): keys to and descriptions of subfamilies, tribes and genera, with designation of types
Life history of the coronate scyphozoan Linuche unguiculata (Swartz, 1788)
Perceptual restoration of obliterated sounds
Mutagenicity studies on two chromium(III) coordination compounds
The formation of the skeleton. I. Growth of a long bone. 1st appearance of a center of calcification
Leucopenia and abnormal liver function in travellers on malaria chemoprophylaxis
The joint commission: four key root causes loom large in sentinel event data
Treatment of vitiligo with topical 15% lactic acid solution in combination with ultra violet-A
Behaviour of dairy cows within three hours after feed supply: I. Influence of housing type and time elapsing after feed supply
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Management and control of patients with type 2 diabetes mellitus in Lebanon: results from the International Diabetes Management Practices Study (IDMPS)
The diet composition and nutritional knowledge of patients with anorexia nervosa
Physoporella croatica Herak, 1958 of the Slovak karst Anisian (Slovakia, the West Carpathians Mts.)
Bright lights, big noise. How effective are vehicle warning systems?
Ein Plesiosaurier-Rest mit Magensteinen aus mittlerem Lias von Quedlinburg
Incidence of Chlamydia trachomatis in patients with sterility
Monster soup: the microscope and Victorian fantasy
Preliminary tests with residual sprays against poultry lice
Duration of the life of plants in phylogeny

Delivery of Antisense Oligonucleotides to the Cornea


Delivery of Antisense Oligonucleotides to the Cornea



Nucleic Acid Therapeutics 30(4): 207-214



ISSN/ISBN: 2159-3337

PMID: 32202944

DOI: 10.1089/nat.2019.0838

Antisense oligonucleotides (ASOs) are synthetic nucleic acids that recognize complementary RNA sequences inside cells and modulate gene expression. In this study, we explore the feasibility of ASO delivery to the cornea. We used quantitative polymerase chain reaction to test the efficacy of a benchmark ASO targeting a noncoding nuclear RNA, Metastasis-Associated Lung Adenocarcinoma Transcript 1 (MALAT1), in a human corneal endothelial cell line, ex vivo human corneas, and in vivo in mice. In vivo delivery was via intravitreal or intracameral injections as well as topical administration. The anti-MALAT1 ASO significantly reduced expression of MALAT1 in a corneal endothelial cell line. We achieved a dose-dependent reduction of target gene expression in endothelial tissue from ex vivo human donor corneas. In vivo mouse experiments confirmed MALAT1 reduction in whole corneal tissue via intravitreal and intracameral routes, 82% and 71% knockdown, respectively (P < 0.001). Effects persisted up to at least 21 days, 32% (P < 0.05) and 43% (P < 0.05) knockdown, respectively. We developed protocols for the isolation and analysis of mouse corneal endothelium and observed reduction in MALAT1 expression upon both intravitreal and intracameral administrations, 64% (P < 0.05) and 63% (P < 0.05) knockdown, respectively. These data open the possibility of using ASOs to treat corneal disease.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 069942415

Download citation: RISBibTeXText

Related references

Molecular Delivery System for Antisense Oligonucleotides: Enhanced Effectiveness of Antisense Oligonucleotides by HVJ-liposome Mediated Transfer. Journal of Cardiovascular Pharmacology and Therapeutics 2(3): 213-222, 1997

Antisense technology: selection and delivery of optimally acting antisense oligonucleotides. Journal of Drug Targeting 5(4): 225-234, 1998

Antisense pharmacodynamics: Critical issues in the transport and delivery of antisense oligonucleotides. Pharmaceutical Research 16(4): 494-502, 1999

Nasal delivery of antisense oligonucleotides: in vitro evaluation of a thiomer/glutathione microparticulate delivery system. Journal of Drug Targeting 18(4): 303-312, 2010

Delivery of antisense oligonucleotides. Spector, D L Author, Goldman, R D Author, Leinwand, L A Author Cells: A Laboratory Manual, Vol 2; Light microscopy and cell structure 89;1-89;19, 1998

Transdermal delivery of antisense oligonucleotides. Methods in Molecular Medicine 106: 255-269, 2005

Novel non-endocytic delivery of antisense oligonucleotides. Advanced Drug Delivery Reviews 44(1): 35-49, 2000

Cellular delivery of antisense oligonucleotides. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik E.V 50(1): 101-119, 2000

Oral delivery of antisense oligonucleotides in man. Journal of Pharmaceutical Sciences 97(1): 225-236, 2008

In vitro delivery of antisense oligonucleotides. Cellular and Molecular Biology Letters 7(2): 236-237, 2002

Antisense oligonucleotides: strategies for delivery. Pharmaceutical Science and Technology Today 1(9): 377-386, 1998

Delivery systems for antisense oligonucleotides. Pharmacology and Therapeutics 87(2-3): 255-277, 2000

Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik E.V 54(3): 263-269, 2002

Delivery of antisense oligonucleotides to the vascular wall. Methods in Molecular Medicine 30: 401-415, 1999

Targeted delivery of antisense oligonucleotides in cancer. Journal of Controlled Release: Official Journal of the Controlled Release Society 74(1-3): 69-75, 2001